Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Gemphire Therapeutics

Gemphire Therapeutics
2008 FOUNDED
PUBLIC STATUS
11-20 EMPLOYEES
GEMP STOCK SYMBOL
$5.63 SHARE PRICE (As of Tuesday Closing)
Description

Developer of novel drugs designed for the treatment of dyslipidemia. The company treats the unmet need of patients with high cardiovascular and pancreatitis risk who are unable to reach optimal LDL cholesterol or triglyceride levels with current therapies - initially targeting orphan indications for fast to market regulatory strategy.

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Other Pharmaceuticals and Biotechnology
Stock Exchange
NAS
Primary Office
  • 17199 North Laurel Park Drive
  • Suite 401
  • Livonia, MI 48152
  • United States

+1 (734) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Gemphire Therapeutics’s full profile, request a free trial.

Gemphire Therapeutics Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
$5.63 - $21.07 $80.1M $5.65 -$3.23 127K 14.2M

Gemphire Therapeutics Financials Summary

In Thousands,
USD
TTM
31-Dec-2017
FY 2017
31-Dec-2017
FY 2016
31-Dec-2016
FY 2015
31-Dec-2015
Enterprise Value 76,049 76,049 48,646
EBITDA (33,129) (33,129) (14,700) (8,267)
Net Income (33,415) (33,415) (14,586) (9,029)
Total Assets 19,017 19,017 24,754 4,490
Total Debt 10,038 10,038 0 6,424
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Gemphire Therapeutics Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Gemphire Therapeutics‘s full profile, request access.

Request full access to PitchBook

Gemphire Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is reserved for PitchBook Platform users. To explore Gemphire Therapeutics‘s full profile, request access.

Request full access to PitchBook
To view this company’s complete Cap Table, request access »

Gemphire Therapeutics Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore Gemphire Therapeutics‘s full profile, request access.

Request full access to PitchBook

Gemphire Therapeutics Executive Team (7)

Name Title Board
Seat
Contact
Info
Jeffrey Mathiesen Chief Financial Officer
David Lowenschuss JD Co-Founder, Chief Legal Officer, Secretary & Board Member
Charles Bisgaier Ph.D Co-Founder, Chief Scientific Officer & Chairman
Seth Reno Chief Commercial Officer
Daniela Oniciu Ph.D Vice President of Preclinical R&D and Manufacturing

1 Former Executive

You’re viewing 5 of 7 executives. Get the full list »

Gemphire Therapeutics Board Members (8)

Name Representing Role Since Contact
Info
Andrew Sassine Self Board Member & Member of Audit and Compensation committees 000 0000
Charles Bisgaier Ph.D Gemphire Therapeutics Co-Founder, Chief Scientific Officer & Chairman 000 0000
David Lowenschuss JD Gemphire Therapeutics Co-Founder, Chief Legal Officer, Secretary & Board Member 000 0000
Kenneth Kousky Self Board Member 000 0000
Kent Hawryluk Self Board Member 000 0000

1 Former Board Member

You’re viewing 5 of 8 board members. Get the full list »